An appraisal of the value of vitamin B12 in the prevention of motion sickness.
Unpublished reports have suggested that hydroxycobalamin (B12, i.m.) prevents motion sickness. Some biomedical evidence supports this contention in that B12 influences the metabolism of histidine and choline; dietary precursors to neurotransmitters with established roles in motion sickness. Susceptibility to motion sickness was evaluated after B12 (1000 micrograms, i.m.). Subjects initially completed vestibular function and motion sickness susceptibility tests to establish normal vestibular function. The experimental motion stressor was a modified coriolis sickness susceptibility test. Subjects executed standardized head movements at successively higher RPM until a malaise III endpoint was reached. Following two baseline tests with this motion stressor, subjects received a B12 injection, a second injection two weeks later, and a final motion sickness test three weeks later. No significant differences in susceptibility were noted after B12. Hematological parameters revealed no B12 deficiency before injection. The possibility that patients with B12 deficiencies are more susceptible to motion sickness cannot be ruled out.
Kohl
R L
RL
Technology Incorporated, Houston, TX 77058, USA.
Lacey
C L
CL
Homick
J L
JL
D000337:Aerospace Medicine; D003312:Coriolis Force; D004198:Disease Susceptibility; D004341:Drug Evaluation; D005260:Female; D019416:Head Movements; D006801:Humans; D006879:Hydroxocobalamin / Q000627:therapeutic use*; D008297:Male; D009041:Motion Sickness / Q000188:drug therapy / Q000517:prevention & control*; D012399:Rotation; D014724:Vestibular Function Tests; D014805:Vitamin B 12 / Q000627:therapeutic use*
D014805:Vitamin B 12; D006879:Hydroxocobalamin